Changeflow GovPing Pharma & Healthcare Monocyte Ratios, APRs, and Sepsis ICU Study
Routine Notice Added Final

Monocyte Ratios, APRs, and Sepsis ICU Study

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH's ClinicalTrials.gov registered a new observational study (NCT07537179) examining whether monocyte distribution, monocyte-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio can serve as biomarkers in sepsis patients in the ICU. The study will enroll patients admitted to the ICU for sepsis or those who develop sepsis during hospitalization, comparing these ratios with conventional acute phase response biomarkers.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

ClinicalTrials.gov published registration for NCT07537179, a new observational study examining monocyte distribution width (MDW), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte ratio (NLR) as potential biomarkers in sepsis patients in the ICU setting. The study will enroll patients admitted to the ICU who either present with sepsis as a primary diagnosis or develop sepsis secondarily.

For clinical investigators and research institutions, this represents an addition to the body of clinical research on sepsis diagnostics. The study may inform future discussions on biomarker utilization in critical care settings but does not create any compliance obligations. Healthcare providers interested in sepsis research may monitor this study for potential implications on clinical practice guidelines.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Investigation of the Relationship Between MD, MLR and NLR With APRs in Sepsis in the ICU

Observational NCT07537179 Kind: OBSERVATIONAL Apr 17, 2026

Abstract

The aim of this study is to investigate, in patients admitted to the intensive care unit either for reasons other than sepsis who subsequently develop sepsis or with a primary diagnosis of sepsis, whether monocyte distribution, monocyte-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio can be used in addition to conventional biomarkers, and to examine their relationships with these biomarkers.

Conditions: Sepsis, Intensive Care (ICU), Acute Phase Biomarkers

Interventions: Monocyte Distribution

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07537179

Who this affects

Applies to
Healthcare providers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Biomarker research Sepsis treatment
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Public Health Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!